Cardioprotective utility of urocortin in myocardial ischemia-reperfusion injury: Where do we stand?

Craig Basman, Pratik Agrawal, Richard Knight, Louis Saravolatz, Chad McRee, Carol Chen-Scarabelli, Jagat Narula, Tiziano Scarabelli

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Background: There has been a constant pursuit for development of newer therapies which can contribute to the relatively nascent field of cardioprotection in the setting of myocardial ischemia-reperfusion injury. One novel cardioprotective agent among others, that has shown promising results in the limited number of research studies undertaken till now, is Urocortin. Urocortins are peptides belonging to the Corticotropin-Releasing Hormone family. Results: Acting through a variety of downstream mechanisms, urocortin has been shown to alter cellular metabolism and modulate the mechanism of cell death occurring as a result of ischemia-reperfusion injury. New evidence continues to accumulate in support of urocortin’s beneficial role in cytoprotection. Conclusion: We present here an updated review largely focused on the various mechanisms through which urocortin alters cellular metabolism, and discuss the clinical potential of urocortin’s cardioprotective ability in myocardial ischemia-reperfusion injury.

Original languageEnglish
Pages (from-to)32-38
Number of pages7
JournalCurrent Molecular Pharmacology
Issue number1
StatePublished - 1 Jan 2018


  • Cell death
  • Cellular metabolism
  • Corticotropins
  • Cytoprotection
  • Ischemia-reperfusion
  • Myocardial
  • Urocortin


Dive into the research topics of 'Cardioprotective utility of urocortin in myocardial ischemia-reperfusion injury: Where do we stand?'. Together they form a unique fingerprint.

Cite this